Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis

S. Adami, J. San Martin, M. Muñoz-Torres, M. J. Econs, L. Xie, G. P. Dalsky, M. McClung, D. Felsenberg, J. P. Brown, M. L. Brandi, A. Sipos

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Summary: Loss of bone mineral density occurs after discontinuation of teriparatide, if no subsequent treatment is given. Sequential raloxifene prevented rapid bone loss at lumbar spine and further increased bone mineral density (BMD) at femoral neck, whether raloxifene was started immediately or after a one-year delay following teriparatide treatment. Introduction: We compared the sequential effects of raloxifene treatment with a placebo on teriparatide-induced increases in bone mineral density (BMD). A year of open-label raloxifene extended the study to assess the response with and without delay after discontinuation of teriparatide. Methods: Following a year of open-label teriparatide 20 μg/day treatment, postmenopausal women with osteoporosis were randomly assigned to raloxifene 60 mg/day (n=157) or a placebo (n=172) for year 2, followed by a year of open-label raloxifene. BMD was measured by dual energy x-ray absorptiometry. Results: The raloxifene and placebo groups showed a decrease in lumbar spine (LS) BMD in year 2 for raloxifene and placebo groups (-1.0±0.3%, P=0.004; and -4.0±0.3%, P<0.001, respectively); the decrease was less with raloxifene (P<0.001). Open-label raloxifene treatment reversed the LS BMD decrease with a placebo, resulting in similar decreases 2 years after randomization (-2.6±0.4% (raloxifene-raloxifene) and -2.7±0.4% (placebo-placebo). At study end, LS and femoral neck (FN) BMD were higher than pre-teriparatide levels, with no significant differences between the raloxifene-raloxifene and placebo-raloxifene groups, respectively (LS: 6.1±0.5% vs. 5.1±0.5%; FN: 3.4±0.6% vs. 3.0±0.5%). Conclusion: Sequential raloxifene prevented rapid bone loss at the LS and increased FN BMD whether raloxifene was started immediately or after a one-year delay following teriparatide treatment.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalOsteoporosis International
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Teriparatide
Osteoporosis
Bone Density
Placebos
Spine
Femur Neck
Therapeutics
Raloxifene Hydrochloride
Bone and Bones

Keywords

  • Antiresorptive therapy
  • Bone mineral density
  • Raloxifene
  • Teriparatide
  • Treatment discontinuation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. / Adami, S.; San Martin, J.; Muñoz-Torres, M.; Econs, M. J.; Xie, L.; Dalsky, G. P.; McClung, M.; Felsenberg, D.; Brown, J. P.; Brandi, M. L.; Sipos, A.

In: Osteoporosis International, Vol. 19, No. 1, 01.01.2008, p. 87-94.

Research output: Contribution to journalArticle

Adami, S, San Martin, J, Muñoz-Torres, M, Econs, MJ, Xie, L, Dalsky, GP, McClung, M, Felsenberg, D, Brown, JP, Brandi, ML & Sipos, A 2008, 'Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis', Osteoporosis International, vol. 19, no. 1, pp. 87-94. https://doi.org/10.1007/s00198-007-0485-y
Adami, S. ; San Martin, J. ; Muñoz-Torres, M. ; Econs, M. J. ; Xie, L. ; Dalsky, G. P. ; McClung, M. ; Felsenberg, D. ; Brown, J. P. ; Brandi, M. L. ; Sipos, A. / Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. In: Osteoporosis International. 2008 ; Vol. 19, No. 1. pp. 87-94.
@article{c321eed03aab469a968dba7b8f0af796,
title = "Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis",
abstract = "Summary: Loss of bone mineral density occurs after discontinuation of teriparatide, if no subsequent treatment is given. Sequential raloxifene prevented rapid bone loss at lumbar spine and further increased bone mineral density (BMD) at femoral neck, whether raloxifene was started immediately or after a one-year delay following teriparatide treatment. Introduction: We compared the sequential effects of raloxifene treatment with a placebo on teriparatide-induced increases in bone mineral density (BMD). A year of open-label raloxifene extended the study to assess the response with and without delay after discontinuation of teriparatide. Methods: Following a year of open-label teriparatide 20 μg/day treatment, postmenopausal women with osteoporosis were randomly assigned to raloxifene 60 mg/day (n=157) or a placebo (n=172) for year 2, followed by a year of open-label raloxifene. BMD was measured by dual energy x-ray absorptiometry. Results: The raloxifene and placebo groups showed a decrease in lumbar spine (LS) BMD in year 2 for raloxifene and placebo groups (-1.0±0.3{\%}, P=0.004; and -4.0±0.3{\%}, P<0.001, respectively); the decrease was less with raloxifene (P<0.001). Open-label raloxifene treatment reversed the LS BMD decrease with a placebo, resulting in similar decreases 2 years after randomization (-2.6±0.4{\%} (raloxifene-raloxifene) and -2.7±0.4{\%} (placebo-placebo). At study end, LS and femoral neck (FN) BMD were higher than pre-teriparatide levels, with no significant differences between the raloxifene-raloxifene and placebo-raloxifene groups, respectively (LS: 6.1±0.5{\%} vs. 5.1±0.5{\%}; FN: 3.4±0.6{\%} vs. 3.0±0.5{\%}). Conclusion: Sequential raloxifene prevented rapid bone loss at the LS and increased FN BMD whether raloxifene was started immediately or after a one-year delay following teriparatide treatment.",
keywords = "Antiresorptive therapy, Bone mineral density, Raloxifene, Teriparatide, Treatment discontinuation",
author = "S. Adami and {San Martin}, J. and M. Mu{\~n}oz-Torres and Econs, {M. J.} and L. Xie and Dalsky, {G. P.} and M. McClung and D. Felsenberg and Brown, {J. P.} and Brandi, {M. L.} and A. Sipos",
year = "2008",
month = "1",
day = "1",
doi = "10.1007/s00198-007-0485-y",
language = "English (US)",
volume = "19",
pages = "87--94",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "1",

}

TY - JOUR

T1 - Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis

AU - Adami, S.

AU - San Martin, J.

AU - Muñoz-Torres, M.

AU - Econs, M. J.

AU - Xie, L.

AU - Dalsky, G. P.

AU - McClung, M.

AU - Felsenberg, D.

AU - Brown, J. P.

AU - Brandi, M. L.

AU - Sipos, A.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Summary: Loss of bone mineral density occurs after discontinuation of teriparatide, if no subsequent treatment is given. Sequential raloxifene prevented rapid bone loss at lumbar spine and further increased bone mineral density (BMD) at femoral neck, whether raloxifene was started immediately or after a one-year delay following teriparatide treatment. Introduction: We compared the sequential effects of raloxifene treatment with a placebo on teriparatide-induced increases in bone mineral density (BMD). A year of open-label raloxifene extended the study to assess the response with and without delay after discontinuation of teriparatide. Methods: Following a year of open-label teriparatide 20 μg/day treatment, postmenopausal women with osteoporosis were randomly assigned to raloxifene 60 mg/day (n=157) or a placebo (n=172) for year 2, followed by a year of open-label raloxifene. BMD was measured by dual energy x-ray absorptiometry. Results: The raloxifene and placebo groups showed a decrease in lumbar spine (LS) BMD in year 2 for raloxifene and placebo groups (-1.0±0.3%, P=0.004; and -4.0±0.3%, P<0.001, respectively); the decrease was less with raloxifene (P<0.001). Open-label raloxifene treatment reversed the LS BMD decrease with a placebo, resulting in similar decreases 2 years after randomization (-2.6±0.4% (raloxifene-raloxifene) and -2.7±0.4% (placebo-placebo). At study end, LS and femoral neck (FN) BMD were higher than pre-teriparatide levels, with no significant differences between the raloxifene-raloxifene and placebo-raloxifene groups, respectively (LS: 6.1±0.5% vs. 5.1±0.5%; FN: 3.4±0.6% vs. 3.0±0.5%). Conclusion: Sequential raloxifene prevented rapid bone loss at the LS and increased FN BMD whether raloxifene was started immediately or after a one-year delay following teriparatide treatment.

AB - Summary: Loss of bone mineral density occurs after discontinuation of teriparatide, if no subsequent treatment is given. Sequential raloxifene prevented rapid bone loss at lumbar spine and further increased bone mineral density (BMD) at femoral neck, whether raloxifene was started immediately or after a one-year delay following teriparatide treatment. Introduction: We compared the sequential effects of raloxifene treatment with a placebo on teriparatide-induced increases in bone mineral density (BMD). A year of open-label raloxifene extended the study to assess the response with and without delay after discontinuation of teriparatide. Methods: Following a year of open-label teriparatide 20 μg/day treatment, postmenopausal women with osteoporosis were randomly assigned to raloxifene 60 mg/day (n=157) or a placebo (n=172) for year 2, followed by a year of open-label raloxifene. BMD was measured by dual energy x-ray absorptiometry. Results: The raloxifene and placebo groups showed a decrease in lumbar spine (LS) BMD in year 2 for raloxifene and placebo groups (-1.0±0.3%, P=0.004; and -4.0±0.3%, P<0.001, respectively); the decrease was less with raloxifene (P<0.001). Open-label raloxifene treatment reversed the LS BMD decrease with a placebo, resulting in similar decreases 2 years after randomization (-2.6±0.4% (raloxifene-raloxifene) and -2.7±0.4% (placebo-placebo). At study end, LS and femoral neck (FN) BMD were higher than pre-teriparatide levels, with no significant differences between the raloxifene-raloxifene and placebo-raloxifene groups, respectively (LS: 6.1±0.5% vs. 5.1±0.5%; FN: 3.4±0.6% vs. 3.0±0.5%). Conclusion: Sequential raloxifene prevented rapid bone loss at the LS and increased FN BMD whether raloxifene was started immediately or after a one-year delay following teriparatide treatment.

KW - Antiresorptive therapy

KW - Bone mineral density

KW - Raloxifene

KW - Teriparatide

KW - Treatment discontinuation

UR - http://www.scopus.com/inward/record.url?scp=36649030841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36649030841&partnerID=8YFLogxK

U2 - 10.1007/s00198-007-0485-y

DO - 10.1007/s00198-007-0485-y

M3 - Article

C2 - 17938984

AN - SCOPUS:36649030841

VL - 19

SP - 87

EP - 94

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 1

ER -